Arizona Alzheimer's Disease Research Center

总体-项目总结/摘要 在过去的20年里，亚利桑那州的研究人员建立了NIA的第一个全州阿尔茨海默病中心， 在阿尔茨海默病（AD）研究方面，美国最广泛的全州合作。他们开创了 对AD异常早期检测、跟踪和研究以及加速AD评估的贡献 预防治疗。该中心包括来自七个组织的研究人员，其中六个在凤凰城 一个在Tucson。它支持了来自全州各组织的150名研究人员， 以产生超过20亿美元的新赠款、合同、慈善、国家和组织投资。 亚利桑那州广告研究中心（ADRC）将利用该中心的领导地位，全州范围内的合作， 模式，主要的组织承诺，广泛共享的科学资源及其存在， 把科学防治AD作为国家的头等大事。其资源、战略计划和相关方案 和预防试验的目的是为有希望的血液检测奠定基础，以改变AD/ADRD 研究，治疗开发和护理，包括来自不同背景的人，找到一个有效的 到2025年，实现国家阿尔茨海默病项目法案（NAPA）的目标。我们将使用ADRC， 组织和慈善基金，提供数据和血液样本的非凡资源， 使用数百份血液样本进行神经病理学研究和BBB对ADRD的诊断验证 在生命的最后几年，大脑捐赠者在死后进行了全面的神经病理学评估。的 中心的总体目标将通过其六个核心和研究中心的协调活动来实现 教育部分。行政核心将为ADRC提供科学领导， 整体多中心临床中心将进行标准评价，并收集所有患者的UDS和其他数据 与会者，包括大量的西班牙裔/拉丁美洲人和美洲原住民的参与者。神经病理学 核心将提供神经病理学诊断和处理，存储和分发死后脑组织，包括 在生命的最后1-2年提供血液样本的人。生物标志物核心将支持和 提供遗传学，脑成像（MRI，淀粉样蛋白PET，tau PET），脑脊液（CSF）和BBB的访问， AD.外展，招聘和参与（ORE）核心将支持临床和 神经病理学核心，提供一系列的教育和推广计划，为健康的成年人，病人和 家庭照顾者在我们中心的集水区，包括从亚利桑那州的大型西班牙裔/拉丁裔和原住民 美国社区。数据管理和统计核心将支持所有数据管理， 核心和中心的信息学和统计需求。REC将与每个核心密切协调 并利用与两个少数民族老龄化研究资源中心（RCMARs）的外部合作伙伴关系， 并支持新的研究人员和临床医生的发展。这些活动将有助于为 对于BBB来说，革命性的ADRD研究，治疗和护理，为临床前AD的研究提供信息，并帮助 提供尽可能好的变化，以发现并支持在2025年批准AD预防治疗。

OVERALL — PROJECT SUMMARY/ABSTRACT Over the last 20 years, Arizona researchers established NIA's first statewide Alzheimer's Disease Center and the nation's most extensive statewide collaboration in Alzheimer's disease (AD) research. They made pioneering contributions to the unusually early detection, tracking and study of AD and the accelerated evaluation of AD prevention therapies. The Center includes researchers from seven organizations, six in the Phoenix metropolitan area and one in Tucson. It has supported 150 researchers from organizations across the state and helping them to generate more than $2 billion in new grants, contracts, philanthropic, state and organizational investments. The Arizona AD Research Center (ADRC) will capitalize on the Center's leadership, statewide collaborative model, major organizational commitments, and extensively shared scientific resources and its very existence to make the scientific fight against AD a top priority in the state. Its resources, strategic plan, and related programs and prevention trials are specifically intended to set the stage for promising blood tests to transform AD/ADRD research, treatment development, and care, include persons from diverse backgrounds, find an effective prevention therapy by 2025, and fulfill National Alzheimer's Project Act (NAPA) goals. We will use ADRC, organizational and philanthropic funds to provide an extraordinary resource of data and blood samples for neuropathological study and diagnostic validation of BBBs for ADRD using blood samples from several hundred brain donors in the last years of life who have comprehensive neuropathological assessments after they die. The overall goals of the Center will be accomplished through coordinated activities of its six Cores and the Research Education Component (REC). The Administrative Core will provide the scientific leadership to the ADRC as a whole. The multi-site Clinical Core will perform standard evaluations and collect UDS and additional data on all participants, including a large number of Hispanic/Latino and Native American participants. The Neuropathology Core will provide neuropathologic diagnoses and process, store and distribute postmortem brain tissue, including from those who provided blood samples in the last 1-2 years of their lives. The Biomarker Core will support and provide access to genetics, brain imaging (MRI, amyloid PET, tau PET), cerebrospinal fluid (CSF) and BBBs of AD. The Outreach, Recruitment and Engagement (ORE) Core will support the efforts of the Clinical and Neuropathology Core, providing a range of educational and outreach programs for healthy adults, patients and family caregivers in our Center's catchment area, including from Arizona's large Hispanic/Latino and Native American communities. The Data Management and Statistics Core will support all the data management, informatics and statistical needs of the Cores and Center. The REC will coordinate closely with each of the Cores and leverage external partnership with two Resource Centers for Minority Aging Research (RCMARs) to attract and support the development of new researchers and clinicians. Together these activities will help set the stage for BBBs to revolutionize ADRD research, treatment and care, inform the study of preclinical AD, and help provide the best possible change to find and support the approval of an AD prevention therapy in 2025.